The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZNTL | -44.84% | -95.9% | -47.17% | -93% |
| S&P | +16.9% | +95.99% | +14.39% | +173% |
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.16M | 51.1% |
| Gross Margin | 98.82% | 0.0% |
| Market Cap | $83.46M | -71.3% |
| Market Cap / Employee | $0.50M | 0.0% |
| Employees | 166 | -1.2% |
| Net Income | -$26.87M | 69.6% |
| EBITDA | -$35.90M | 44.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $37.60M | 1.7% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $37.69M | -8.8% |
| Short Term Debt | $3.63M | 33.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.60% | -3.6% |
| Return On Invested Capital | -46.24% | 5.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34.71M | 1.7% |
| Operating Free Cash Flow | -$34.71M | 1.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.68 | 0.61 | 0.34 | 0.28 | -55.36% |
| Price to Sales | 6.45 | 3.20 | 4.24 | 3.11 | -56.61% |
| Price to Tangible Book Value | 0.69 | 0.61 | 0.34 | 0.28 | -55.73% |
| Enterprise Value to EBITDA | 1.69 | 2.46 | 4.94 | 4.98 | 251.29% |
| Return on Equity | -42.9% | -42.8% | -59.5% | -49.5% | 15.27% |
| Total Debt | $43.27M | $42.65M | $38.65M | $41.32M | -6.16% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
